1932

Abstract

The use of ex vivo drug sensitivity testing to predict drug activity in individual patients has been actively explored for almost 50 years without delivering a generally useful predictive capability. However, extended failure should not be an indicator of futility. This is especially true in cancer research, where ultimate success is often preceded by less successful attempts. For example, both immune- and genetic-based targeted therapies for cancer underwent numerous failed attempts before biological understanding, improved targets, and optimized drug development matured to facilitate an arsenal of transformational drugs. Similarly, directly assessing drug sensitivity of primary tumor biopsies—and the use of this information to help direct therapeutic approaches—has a long history with a definitive learningcurve. In this review, we survey the history of ex vivo testing and the current state of the art for this field. We present an update on methodologies and approaches, describe the use of these technologies to test cutting-edge drug classes, and describe an increasingly nuanced understanding of tumor types and models for which this strategy is most likely to succeed. We consider the relative strengths and weaknesses of predicting drug activity across the broad biological context of cancer patients and tumor types. This includes an analysis of the potential for ex vivo drug sensitivity testing to accurately predict drug activity within each of the biological hallmarks of cancer pathogenesis.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-cancerbio-043020-125955
2021-03-04
2024-06-17
Loading full text...

Full text loading...

/deliver/fulltext/cancerbio/5/1/annurev-cancerbio-043020-125955.html?itemId=/content/journals/10.1146/annurev-cancerbio-043020-125955&mimeType=html&fmt=ahah

Literature Cited

  1. Amann A, Zwierzina M, Gamerith G, Bitsche M, Huber JM et al. 2014. Development of an innovative 3D cell culture system to study tumour–stroma interactions in non-small cell lung cancer cells. PLOS ONE 9:3e92511
    [Google Scholar]
  2. Ashok A, Choudhury D, Fang Y, Hunziker W 2020. Towards manufacturing of human organoids. Biotechnol. Adv. 39:107460
    [Google Scholar]
  3. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE et al. 2010. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329:59971345–48
    [Google Scholar]
  4. Bouchez LC, Boitano AE, de Lichtervelde L, Romeo R, Cooke MP, Schultz PG 2011. Small-molecule regulators of human stem cell self-renewal. Chembiochem 12:6854–57
    [Google Scholar]
  5. Bradley TR, Metcalf D. 1966. The growth of mouse bone marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci 44:3287–99
    [Google Scholar]
  6. Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC 2020. Could 3D models of cancer enhance drug screening. ? Biomaterials 232:119744
    [Google Scholar]
  7. Brodin BA, Wennerberg K, Lidbrink E, Brosjo O, Potdar S et al. 2019. Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. Br. J. Cancer 120:4435–43
    [Google Scholar]
  8. Brouzes E, Medkova M, Savenelli N, Marran D, Twardowski M et al. 2009. Droplet microfluidic technology for single-cell high-throughput screening. PNAS 106:3414195–200
    [Google Scholar]
  9. Brower SL, Fensterer JE, Bush JE 2008. The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol. Biol. 414:57–78
    [Google Scholar]
  10. Burstein HJ, Mangu PB, Somerfield MR, Schrag D, Samson D et al. 2011. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 29:243328–30
    [Google Scholar]
  11. Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E et al. 2017. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep 18:133204–18
    [Google Scholar]
  12. Cellot S, Hope KJ, Chagraoui J, Sauvageau M, Deneault E et al. 2013. RNAi screen identifies Jarid1b as a major regulator of mouse HSC activity. Blood 122:91545–55
    [Google Scholar]
  13. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S et al. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9:5351–65
    [Google Scholar]
  14. Chagraoui J, Lehnertz B, Girard S, Spinella JF, Fares I et al. 2019. UM171 induces a homeostatic inflammatory-detoxification response supporting human HSC self-renewal. PLOS ONE 14:11e0224900
    [Google Scholar]
  15. Chou DB, Frismantas V, Milton Y, David R, Pop-Damkov P et al. 2020. On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology. Nat. Biomed. Eng. 4:394–406
    [Google Scholar]
  16. Clevers H, Tuveson DA. 2019. Organoid models for cancer research. Annu. Rev. Cancer Biol. 3:223–34
    [Google Scholar]
  17. Cortazar P, Gazdar AF, Woods E, Russell E, Steinberg SM et al. 1997. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin. Cancer Res. 3:5741–47
    [Google Scholar]
  18. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S 2007. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs 18:91093–101
    [Google Scholar]
  19. Crespo M, Vilar E, Tsai SY, Chang K, Amin S et al. 2017. Colonic organoids derived from human induced pluripotent stem cells for modeling colorectal cancer and drug testing. Nat. Med. 23:7878–84
    [Google Scholar]
  20. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A 2007. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Investig. 117:1112–21
    [Google Scholar]
  21. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID 2010. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat. Med. 16:2232–36
    [Google Scholar]
  22. Deneault E, Cellot S, Faubert A, Laverdure JP, Frechette M et al. 2009. A functional screen to identify novel effectors of hematopoietic stem cell activity. Cell 137:2369–79
    [Google Scholar]
  23. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A 2007. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12:2171–85
    [Google Scholar]
  24. Dietrich S, Oles M, Lu J, Sellner L, Anders S et al. 2018. Drug-perturbation-based stratification of blood cancer. J. Clin. Investig. 128:1427–45
    [Google Scholar]
  25. Edwards DK 5th, Watanabe-Smith K, Rofelty A, Damnernsawad A, Laderas T et al. 2019. CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cells. Blood 133:6588–99
    [Google Scholar]
  26. Edwards DK 5th, Sweeney DT, Ho H, Eide CA, Rofelty A et al. 2018. Targeting of colony-stimulating factor 1 receptor (CSF1R) in the CLL microenvironment yields antineoplastic activity in primary patient samples. Oncotarget 9:3724576–89
    [Google Scholar]
  27. Eltabbakh GH, Piver MS, Hempling RE, Recio FO, Lele SB et al. 1998. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol. Oncol. 70:3392–97
    [Google Scholar]
  28. Fan H, Demirci U, Chen P 2019. Emerging organoid models: leaping forward in cancer research. J. Hematol. Oncol. 12:1142
    [Google Scholar]
  29. Fares I, Chagraoui J, Gareau Y, Gingras S, Ruel R et al. 2014. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 345:62031509–12
    [Google Scholar]
  30. Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, Hogge DE 2003. Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17:4760–63
    [Google Scholar]
  31. Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S et al. 2015. Genomics and drug profiling of fatal TCF3-HLF–positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat. Genet. 47:91020–29
    [Google Scholar]
  32. Frazier JP, Bertout JA, Kerwin WS, Moreno-Gonzalez A, Casalini JR et al. 2017. Multidrug analyses in patients distinguish efficacious cancer agents based on both tumor cell killing and immunomodulation. Cancer Res 77:112869–80
    [Google Scholar]
  33. Friedman AA, Letai A, Fisher DE, Flaherty KT 2015. Precision medicine for cancer with next-generation functional diagnostics. Nat. Rev. Cancer 15:12747–56
    [Google Scholar]
  34. Friedman AA, Xia Y, Trippa L, Le LP, Igras V et al. 2017. Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. Clin. Cancer Res. 23:164680–92
    [Google Scholar]
  35. Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH et al. 2017. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. Blood 129:11e26–37
    [Google Scholar]
  36. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T et al. 2006. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int. J. Gynecol. Cancer 16:1194–201
    [Google Scholar]
  37. Gazdar AF, Steinberg SM, Russell EK, Linnoila RI, Oie HK et al. 1990. Correlation of in vitro drug-sensitivity testing results with response to chemotherapy and survival in extensive-stage small cell lung cancer: a prospective clinical trial. J. Natl. Cancer Inst. 82:2117–24
    [Google Scholar]
  38. Hanahan D, Coussens LM. 2012. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21:3309–22
    [Google Scholar]
  39. Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:5646–74
    [Google Scholar]
  40. Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT et al. 2014. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov 4:9998–1013
    [Google Scholar]
  41. Hirt C, Papadimitropoulos A, Mele V, Muraro MG, Mengus C et al. 2014. “In vitro” 3D models of tumor-immune system interaction. Adv. Drug Deliv. Rev. 79–80:145–54
    [Google Scholar]
  42. Hoffman RM. 2015. Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat. Rev. Cancer 15:8451–52
    [Google Scholar]
  43. Hope KJ, Cellot S, Ting SB, MacRae T, Mayotte N et al. 2010. An RNAi screen identifies Msi2 and Prox1 as having opposite roles in the regulation of hematopoietic stem cell activity. Cell Stem Cell 7:1101–13
    [Google Scholar]
  44. Hudson WA, Li Q, Le C, Kersey JH 1998. Xenotransplantation of human lymphoid malignancies is optimized in mice with multiple immunologic defects. Leukemia 12:122029–33
    [Google Scholar]
  45. Ince TA, Sousa AD, Jones MA, Harrell JC, Agoston ES et al. 2015. Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours. Nat. Commun. 6:7419
    [Google Scholar]
  46. Iscove NN, Sieber F, Winterhalter KH 1974. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J. Cell Physiol. 83:2309–20
    [Google Scholar]
  47. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M et al. 2002. NOD/SCID/γcnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100:93175–82
    [Google Scholar]
  48. Jacob T, Agarwal A, Ramunno-Johnson D, O'Hare T, Gonen M et al. 2016. Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting. Sci. Rep. 6:28163
    [Google Scholar]
  49. Jiang T, Munguia-Lopez JG, Gu K, Bavoux MM, Flores-Torres S et al. 2019. Engineering bioprintable alginate/gelatin composite hydrogels with tunable mechanical and cell adhesive properties to modulate tumor spheroid growth kinetics. Biofabrication 12:1015024
    [Google Scholar]
  50. Jonas O, Landry HM, Fuller JE, Santini JT Jr, Baselga J et al. 2015. An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors. Sci. Transl. Med. 7:284284ra57
    [Google Scholar]
  51. Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB et al. 2016. Parallel in-vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities. Clin. Cancer Res. 22:6031–38
    [Google Scholar]
  52. Joo WD, Lee JY, Kim JH, Yoo HJ, Roh HJ et al. 2009. Efficacy of taxane and platinum-based chemotherapy guided by extreme drug resistance assay in patients with epithelial ovarian cancer. J. Gynecol. Oncol. 20:296–100
    [Google Scholar]
  53. Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK et al. 2017. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell–induced protection of AML. Blood 130:6789–802
    [Google Scholar]
  54. Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY et al. 2015. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat. Commun. 6:6220
    [Google Scholar]
  55. Kern DH. 1998. Heterogeneity of drug resistance in human breast and ovarian cancers. Cancer J. Sci. Am. 4:141–45
    [Google Scholar]
  56. Kern DH, Drogemuller CR, Kennedy MC, Hildebrand-Zanki SU, Tanigawa N, Sondak VK 1985. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors. Cancer Res 45:11 Pt. 15436–41
    [Google Scholar]
  57. Kern DH, Weisenthal LM. 1990. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J. Natl. Cancer Inst. 82:7582–88
    [Google Scholar]
  58. Klinghoffer RA, Bahrami SB, Hatton BA, Frazier JP, Moreno-Gonzalez A et al. 2015. A technology platform to assess multiple cancer agents simultaneously within a patient's tumor. Sci. Transl. Med. 7:284284ra58
    [Google Scholar]
  59. Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L et al. 2016. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov 6:101106–17
    [Google Scholar]
  60. Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA et al. 1998. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9:151–57
    [Google Scholar]
  61. Kuusanmaki H, Leppa AM, Polonen P, Kontro M, Dufva O et al. 2020. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica 105:3708–20
    [Google Scholar]
  62. Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P 2017. Current status and perspectives of patient-derived xenograft models in cancer research. J. Hematol. Oncol. 10:1106
    [Google Scholar]
  63. Langer EM, Allen-Petersen BL, King SM, Kendsersky ND, Turnidge MA et al. 2019. Modeling tumor phenotypes in vitro with three-dimensional bioprinting. Cell Rep 26:3608–23.e6
    [Google Scholar]
  64. Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ et al. 2018. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat. Commun. 9:142
    [Google Scholar]
  65. Letai AG. 2008. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat. Rev. Cancer 8:2121–32
    [Google Scholar]
  66. Liu X, Krawczyk E, Suprynowicz FA, Palechor-Ceron N, Yuan H et al. 2017. Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. Nat. Protoc. 12:2439–51
    [Google Scholar]
  67. Liu X, Ory V, Chapman S, Yuan H, Albanese C et al. 2012. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 180:2599–607
    [Google Scholar]
  68. Loizzi V, Chan JK, Osann K, Cappuccini F, DiSaia PJ, Berman ML 2003. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am. J. Obstet. Gynecol. 189:51301–7
    [Google Scholar]
  69. MacPherson L, Anokye J, Yeung MM, Lam EYN, Chan YC et al. 2020. HBO1 is required for the maintenance of leukaemia stem cells. Nature 577:7789266–70
    [Google Scholar]
  70. Maenpaa JU, Heinonen E, Hinkka SM, Karnani P, Klemi PJ et al. 1995. The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial. Gynecol. Oncol. 57:3294–98
    [Google Scholar]
  71. Majumder B, Baraneedharan U, Thiyagarajan S, Radhakrishnan P, Narasimhan H et al. 2015. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. Nat. Commun. 6:6169
    [Google Scholar]
  72. Majumder MM, Leppa AM, Hellesoy M, Dowling P, Malyutina A et al. 2019. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types. Haematologica 105:61527–38
    [Google Scholar]
  73. McAuliffe PF, Evans KW, Akcakanat A, Chen K, Zheng X et al. 2015. Ability to generate patient-derived breast cancer xenografts is enhanced in chemoresistant disease and predicts poor patient outcomes. PLOS ONE 10:9e0136851
    [Google Scholar]
  74. Mehta RS, Bornstein R, Yu IR, Parker RJ, McLaren CE et al. 2001. Breast cancer survival and in vitro tumor response in the extreme drug resistance assay. Breast Cancer Res. Treat. 66:3225–37
    [Google Scholar]
  75. Meyerrose TE, Herrbrich P, Hess DA, Nolta JA 2003. Immune-deficient mouse models for analysis of human stem cells. Biotechniques 35:61262–72
    [Google Scholar]
  76. Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea R et al. 2008. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 28:3B1733–40
    [Google Scholar]
  77. Montero J, Letai A. 2016. Dynamic BH3 profiling-poking cancer cells with a stick. Mol. Cell Oncol. 3:3e1040144
    [Google Scholar]
  78. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J et al. 2015. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160:5977–89
    [Google Scholar]
  79. Moser R, Xu C, Kao M, Annis J, Lerma LA et al. 2014. Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin. Cancer Res. 20:164274–88
    [Google Scholar]
  80. Nagourney RA. 2000. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer. Gynecol. Oncol. 76:1143
    [Google Scholar]
  81. Nagourney RA, Blitzer JB, Shuman RL, Asciuto TJ, Deo EA et al. 2012. Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer. Anticancer Res 32:104453–60
    [Google Scholar]
  82. Neal JT, Kuo CJ. 2016. Organoids as models for neoplastic transformation. Annu. Rev. Pathol. 11:199–220
    [Google Scholar]
  83. Neal JT, Li X, Zhu J, Giangarra V, Grzeskowiak CL et al. 2018. Organoid modeling of the tumor immune microenvironment. Cell 175:71972–88.e16
    [Google Scholar]
  84. Ootani A, Li X, Sangiorgi E, Ho QT, Ueno H et al. 2009. Sustained in vitro intestinal epithelial culture within a Wnt-dependent stem cell niche. Nat. Med. 15:6701–6
    [Google Scholar]
  85. Pabst C, Krosl J, Fares I, Boucher G, Ruel R et al. 2014. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat. Methods 11:4436–42
    [Google Scholar]
  86. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L et al. 2014. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4:3362–75
    [Google Scholar]
  87. Papapetrou EP. 2016. Patient-derived induced pluripotent stem cells in cancer research and precision oncology. Nat. Med. 22:121392–401
    [Google Scholar]
  88. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T et al. 2017. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov 7:5462–77
    [Google Scholar]
  89. Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S et al. 2013. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 3:121416–29
    [Google Scholar]
  90. Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D et al. 2019. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun. Biol. 2:78
    [Google Scholar]
  91. Pike BL, Robinson WA. 1970. Human bone marrow colony growth in agar-gel. J. Cell Physiol. 76:177–84
    [Google Scholar]
  92. Potdar S, Ianevski A, Mpindi JP, Bychkov D, Fiere C et al. 2020. Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics 36:3602–4
    [Google Scholar]
  93. Prina-Mello A, Jain N, Liu B, Kilpatrick JI, Tutty MA et al. 2018. Culturing substrates influence the morphological, mechanical and biochemical features of lung adenocarcinoma cells cultured in 2D or 3D. Tissue Cell 50:15–30
    [Google Scholar]
  94. Ramamoorthy P, Thomas SM, Kaushik G, Subramaniam D, Chastain KM et al. 2019. Metastatic tumor-in-a-dish, a novel multicellular organoid to study lung colonization and predict therapeutic response. Cancer Res 79:71681–95
    [Google Scholar]
  95. Reinisch A, Thomas D, Corces MR, Zhang X, Gratzinger D et al. 2016. A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nat. Med. 22:7812–21
    [Google Scholar]
  96. Ridky TW, Chow JM, Wong DJ, Khavari PA 2010. Invasive three-dimensional organotypic neoplasia from multiple normal human epithelia. Nat. Med. 16:121450–55
    [Google Scholar]
  97. Ryan J, Letai A. 2013. BH3 profiling in whole cells by fluorimeter or FACS. Methods 61:2156–64
    [Google Scholar]
  98. Saeed K, Ojamies P, Pellinen T, Eldfors S, Turkki R et al. 2019. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells. Int. J. Cancer 144:61356–66
    [Google Scholar]
  99. Saeed K, Rahkama V, Eldfors S, Bychkov D, Mpindi JP et al. 2017. Comprehensive drug testing of patient-derived conditionally reprogrammed cells from castration-resistant prostate cancer. Eur. Urol. 71:3319–27
    [Google Scholar]
  100. Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE 1978. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N. Engl. J. Med. 298:241321–27
    [Google Scholar]
  101. Samson DJ, Seidenfeld J, Ziegler K, Aronson N 2004. Chemotherapy sensitivity and resistance assays: a systematic review. J. Clin. Oncol. 22:173618–30
    [Google Scholar]
  102. Sato T, Stange DE, Ferrante M, Vries RG, van Es JH et al. 2011. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141:51762–72
    [Google Scholar]
  103. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N et al. 2009. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 459:7244262–65
    [Google Scholar]
  104. Schmidt SK, Schmid R, Arkudas A, Kengelbach-Weigand A, Bosserhoff AK 2019. Tumor cells develop defined cellular phenotypes after 3D-bioprinting in different bioinks. Cells 8:101295
    [Google Scholar]
  105. Schneeberger K, Spee B, Costa P, Sachs N, Clevers H, Malda J 2017. Converging biofabrication and organoid technologies: the next frontier in hepatic and intestinal tissue engineering. ? Biofabrication 9:1013001
    [Google Scholar]
  106. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD et al. 2004. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J. Clin. Oncol. 22:173631–38
    [Google Scholar]
  107. Shaw GL, Gazdar AF, Phelps R, Linnoila RI, Ihde DC et al. 1993. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53:215181–87
    [Google Scholar]
  108. Shultz LD, Ishikawa F, Greiner DL 2007. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7:2118–30
    [Google Scholar]
  109. Sieber S, Wirth L, Cavak N, Koenigsmark M, Marx U et al. 2018. Bone marrow-on-a-chip: long-term culture of human haematopoietic stem cells in a three-dimensional microfluidic environment. J. Tissue Eng. Regen. Med. 12:2479–89
    [Google Scholar]
  110. Skardal A, Murphy SV, Devarasetty M, Mead I, Kang HW et al. 2017. Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform. Sci. Rep. 7:18837
    [Google Scholar]
  111. Smith R, Devlin K, Kilburn D, Gross S, Sudar D et al. 2019. Using microarrays to interrogate microenvironmental impact on cellular phenotypes in cancer. J. Vis. Exp. 147: 10.3791/58957
    [Google Scholar]
  112. Soslow RA, Slomovitz BM, Saqi A, Baergen RN, Caputo TA 2000. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Mullerian serous carcinomas: clinical divergence without immunophenotypic differences. Gynecol. Oncol. 79:3430–37
    [Google Scholar]
  113. Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS et al. 2016. Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat. Biotechnol. 34:111161–67
    [Google Scholar]
  114. Suprynowicz FA, Upadhyay G, Krawczyk E, Kramer SC, Hebert JD et al. 2012. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. PNAS 109:4920035–40
    [Google Scholar]
  115. Teh CE, Gong JN, Segal D, Tan T, Vandenberg CJ et al. 2020. Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death Differ 27:2217–33
    [Google Scholar]
  116. Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN et al. 2016. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 30:3761–64
    [Google Scholar]
  117. Tuveson D, Clevers H. 2019. Cancer modeling meets human organoid technology. Science 364:6444952–55
    [Google Scholar]
  118. Tyner JW, Deininger MW, Loriaux MM, Chang BH, Gotlib JR et al. 2009. RNAi screen for rapid therapeutic target identification in leukemia patients. PNAS 106:218695–700
    [Google Scholar]
  119. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE et al. 2018. Functional genomic landscape of acute myeloid leukaemia. Nature 562:7728526–31
    [Google Scholar]
  120. Tyner JW, Yang WF, Bankhead A, Fan G, Fletcher LB et al. 2013. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res 73:1285–96
    [Google Scholar]
  121. Ugurel S, Schadendorf D, Pfohler C, Neuber K, Thoelke A et al. 2006. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin. Cancer Res. 12:185454–63
    [Google Scholar]
  122. Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G et al. 2010. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. PNAS 107:188352–56
    [Google Scholar]
  123. Von Hoff DD, Clark GM, Stogdill BJ, Sarosdy MF, O'Brien MT et al. 1983. Prospective clinical trial of a human tumor cloning system. Cancer Res 43:41926–31
    [Google Scholar]
  124. Von Hoff DD, Kronmal R, Salmon SE, Turner J, Green JB et al. 1991. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 67:120–27
    [Google Scholar]
  125. Von Hoff DD, Sandbach JF, Clark GM, Turner JN, Forseth BF et al. 1990. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J. Natl. Cancer Inst. 82:2110–16
    [Google Scholar]
  126. Watson SS, Dane M, Chin K, Tatarova Z, Liu M et al. 2018. Microenvironment-mediated mechanisms of resistance to HER2 inhibitors differ between HER2+ breast cancer subtypes. Cell Syst 6:3329–42.e6
    [Google Scholar]
  127. Wilbur DW, Camacho ES, Hilliard DA, Dill PL, Weisenthal LM 1992. Chemotherapy of non-small cell lung carcinoma guided by an in vitro drug resistance assay measuring total tumour cell kill. Br. J. Cancer 65:127–32
    [Google Scholar]
  128. Wu B, Zhu JS, Zhang Y, Shen WM, Zhang Q 2008. Predictive value of MTT assay as an in vitro chemosensitivity testing for gastric cancer: one institution's experience. World J. Gastroenterol. 14:193064–68
    [Google Scholar]
  129. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C et al. 1998. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer 77:6887–94
    [Google Scholar]
  130. Xu C, Nikolova O, Basom RS, Mitchell RM, Shaw R et al. 2018. Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer. Clin. Cancer Res. 24:122828–43
    [Google Scholar]
  131. Xu JM, Song ST, Tang ZM, Jiang ZF, Liu XQ et al. 1999. Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro. Breast Cancer Res. Treat. 53:177–85
    [Google Scholar]
  132. Yu M, Bardia A, Aceto N, Bersani F, Madden MW et al. 2014. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 345:6193216–20
    [Google Scholar]
  133. Yuan H, Myers S, Wang J, Zhou D, Woo JA et al. 2012. Use of reprogrammed cells to identify therapy for respiratory papillomatosis. N. Engl. J. Med. 367:131220–27
    [Google Scholar]
/content/journals/10.1146/annurev-cancerbio-043020-125955
Loading
/content/journals/10.1146/annurev-cancerbio-043020-125955
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error